• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 患者对 SARS-CoV-2 及其关注变异株的中和抗体的免疫逃逸和滴度随时间推移而下降。

Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients.

机构信息

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.

出版信息

Clin Immunol. 2022 May;238:108999. doi: 10.1016/j.clim.2022.108999. Epub 2022 Apr 7.

DOI:10.1016/j.clim.2022.108999
PMID:35398519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8988444/
Abstract

Many variants of SARS-CoV-2 have emerged, and decreased neutralizing antibodies after vaccination and breakthrough infections have become a problem. The importance of monitoring titers of neutralizing antibodies is getting higher. We enrolled 146 COVID-19 patients, who were thought to be infected with Wuhan-hu-1 or D614G strains, and examined the time course of neutralizing titers against six concerning strains (Wuhan-hu-1, Alpha, Beta, Gamma, Kappa, and Delta) using newly developed ELISA. The acquisition of neutralizing titer was positively associated with disease severity. Immune evasions were observed approximately 20 to 30% for Alpha, Kappa, and Delta variant, and 40 to 45% for Beta and Gamma variant. The titers against all strains decreased over time, and interestingly, while titers against Wuhan-hu-1 decreased by 23%, those to Delta variant decreased by 70%. Our simple, cost-effective, and non-hazardous system will be applicable to process numerous samples, such as monitoring titers against prevalent strains after infection or vaccination.

摘要

已经出现了许多 SARS-CoV-2 的变体,疫苗接种和突破感染后中和抗体滴度下降已成为一个问题。监测中和抗体滴度的重要性越来越高。我们招募了 146 名 COVID-19 患者,他们被认为感染了武汉株或 D614G 株,并使用新开发的 ELISA 检测了针对六种关注株(武汉株、Alpha、Beta、Gamma、Kappa 和 Delta)的中和抗体滴度的时间过程。中和抗体滴度的获得与疾病严重程度呈正相关。大约观察到 Alpha、Kappa 和 Delta 变体有 20%到 30%的免疫逃逸,而 Beta 和 Gamma 变体有 40%到 45%的免疫逃逸。所有株的抗体滴度随时间下降,有趣的是,武汉株的抗体滴度下降了 23%,而 Delta 变体的抗体滴度下降了 70%。我们的简单、经济实惠且无危险的系统将适用于处理大量样本,例如在感染或接种疫苗后监测针对流行株的抗体滴度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/0ffc55a5f80e/mmc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/a543028a13c7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/0a9925312aa5/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/a99a71040583/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/a875a1aa26bf/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/586abb323bee/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/0ffc55a5f80e/mmc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/a543028a13c7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/0a9925312aa5/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/a99a71040583/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/a875a1aa26bf/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/586abb323bee/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e891/8988444/0ffc55a5f80e/mmc1_lrg.jpg

相似文献

1
Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients.COVID-19 患者对 SARS-CoV-2 及其关注变异株的中和抗体的免疫逃逸和滴度随时间推移而下降。
Clin Immunol. 2022 May;238:108999. doi: 10.1016/j.clim.2022.108999. Epub 2022 Apr 7.
2
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.COVID-19 康复者感染后 1 年的 SARS-CoV-2 特异性抗体和 T 细胞反应:一项纵向队列研究。
Lancet Microbe. 2022 May;3(5):e348-e356. doi: 10.1016/S2666-5247(22)00036-2. Epub 2022 Mar 23.
3
Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19.COVID-19 康复患者体内针对 SARS-CoV-2 不同变体的中和抗体演变及交叉反应性。
J Formos Med Assoc. 2023 Aug;122(8):714-722. doi: 10.1016/j.jfma.2022.11.015. Epub 2022 Nov 29.
4
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.感染和接种后对 SARS-CoV-2 的异源中和活性。
Front Immunol. 2022 May 30;13:888794. doi: 10.3389/fimmu.2022.888794. eCollection 2022.
5
Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.辉瑞疫苗(BNT162b2)接种者体内针对三种活 SARS-CoV-2 变异株的抗-S IgG 与中和抗体滴度的相关性。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2105611. doi: 10.1080/21645515.2022.2105611. Epub 2022 Sep 12.
6
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.恢复期血浆捐献者在免疫接种后对 SARS-CoV-2 的抗原变异体表现出增强的交叉反应性中和抗体反应。
Transfusion. 2022 Jul;62(7):1347-1354. doi: 10.1111/trf.16934. Epub 2022 Jun 2.
7
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.卫星五号疫苗接种后的纵向研究显示,随着时间的推移,SARS-CoV-2 中和抗体具有持久性,并且对病毒变异的中和逃逸能力降低。
mBio. 2022 Feb 22;13(1):e0344221. doi: 10.1128/mbio.03442-21. Epub 2022 Jan 25.
8
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.东京一家转诊医院医护人员中2019冠状病毒病(COVID-19)突破性感染及接种疫苗后的中和抗体:一项病例对照匹配研究
Clin Infect Dis. 2022 Aug 24;75(1):e683-e691. doi: 10.1093/cid/ciab1048.
9
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体,提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
10
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.

引用本文的文献

1
Risk factors of cytomegalovirus reactivation in patients with rheumatic musculoskeletal diseases undergoing remission induction therapy with high-dose glucocorticoids; a prospective short-term cohort study.接受大剂量糖皮质激素缓解诱导治疗的风湿性肌肉骨骼疾病患者巨细胞病毒再激活的危险因素;一项前瞻性短期队列研究。
Clin Rheumatol. 2025 Aug 12. doi: 10.1007/s10067-025-07609-3.
2
Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies.体液免疫和系统性红斑狼疮人群呼吸道病毒疫苗的安全性:基于 25 项观察性研究的荟萃分析。
Ann Med. 2024 Dec;56(1):2392882. doi: 10.1080/07853890.2024.2392882. Epub 2024 Aug 19.
3

本文引用的文献

1
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.接种疫苗后对关注的 Delta(B.1.617.2)SARS-CoV-2 变异株的中和作用降低。
PLoS Pathog. 2021 Dec 2;17(12):e1010022. doi: 10.1371/journal.ppat.1010022. eCollection 2021 Dec.
2
Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study.COVID-19 患者抗体的动态特征分析:一项为期 13 个月的研究。
Front Immunol. 2021 Jul 20;12:708184. doi: 10.3389/fimmu.2021.708184. eCollection 2021.
3
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
Antibody level dynamics until after the third dose of COVID-19 vaccination.
直至第三剂新冠疫苗接种后的抗体水平动态变化。
Heliyon. 2023 Jun 22;9(7):e17477. doi: 10.1016/j.heliyon.2023.e17477.
4
Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents.从康复者的双抗原特异性B细胞产生的针对新冠病毒的强效中和性广谱抗体。
iScience. 2023 Jun 16;26(6):106955. doi: 10.1016/j.isci.2023.106955. Epub 2023 May 25.
5
The importance of equally accessible genomic surveillance in the age of pandemics.大流行时代同样可及的基因组监测的重要性。
Biol Futur. 2023 Jun;74(1-2):81-89. doi: 10.1007/s42977-023-00164-5. Epub 2023 May 18.
6
Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test.验证和建立 SARS-CoV-2 慢病毒替代中和测定法作为蚀斑减少中和试验的预筛选工具。
Microbiol Spectr. 2023 Feb 14;11(1):e0378922. doi: 10.1128/spectrum.03789-22. Epub 2023 Jan 5.
7
Recent advances in point of care testing for COVID-19 detection.即时检测在 COVID-19 检测中的最新进展。
Biomed Pharmacother. 2022 Sep;153:113538. doi: 10.1016/j.biopha.2022.113538. Epub 2022 Aug 12.
8
Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients.接种疫苗的类风湿关节炎患者体内抗SARS-CoV-2刺突抗体滴度和中和抗体情况
Vaccines (Basel). 2022 Aug 21;10(8):1365. doi: 10.3390/vaccines10081365.
新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
4
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2(德尔塔)变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
5
Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.疫苗免疫血清样本对SARS-CoV-2及P.1变异株的年龄依赖性中和作用
JAMA. 2021 Jul 21;326(9):868-9. doi: 10.1001/jama.2021.11656.
6
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.SARS-CoV-2 变体 B.1.617 对巴美洛单抗具有耐药性,并能逃避由感染和接种疫苗引起的抗体。
Cell Rep. 2021 Jul 20;36(3):109415. doi: 10.1016/j.celrep.2021.109415. Epub 2021 Jun 29.
7
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.高通量细胞和无病毒检测表明,COVID-19 恢复期血浆对 SARS-CoV-2 变体的中和作用降低。
Sci Transl Med. 2021 Aug 4;13(605). doi: 10.1126/scitranslmed.abi8452. Epub 2021 Jul 13.
8
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.COVID-19 恢复期个体中中和抗体的时间成熟提高了对流行的 SARS-CoV-2 变体的效力和广度。
Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2.
9
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
10
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)B.1.617变体的感染及疫苗诱导的中和抗体反应
N Engl J Med. 2021 Aug 12;385(7):664-666. doi: 10.1056/NEJMc2107799. Epub 2021 Jul 7.